Higher expression of Rif is associated with poorer clinical outcomes and contributes to cell proliferation and invasion in some cancers, including pancreatic adenocarcinoma (38) and hepatocellular carcinoma (36). Here, RHOF is linked to hepatocellular carcinoma.